China's Vaccine Market Gets Boost From Government Cash Injections
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Vaccine makers, both global and domestic, face extraordinary opportunities in China as the government tackles preventable diseases as part of its push to expand healthcare services
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010
Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
Pfizer Vaccines President Mark Swindell On Prevenar 13 in Developing Countries And Emerging Markets: An Interview With PharmAsia News
Pfizer and GlaxoSmithKline attracted attention earlier this year while finalizing an agreement with the public-private GAVI Alliance to bring the newest pneumococcal vaccines - Prevenar 13 and Synflorix, respectively - to developing countries. Pfizer announced in August that the World Health Organization granted prequalification status to Prevenar 13, a condition for the drug to be used by United Nations agencies, including UNICEF. Pfizer Vaccines President Mark Swindell spoke with PharmAsia News following the WHO announcement to discuss the company's vaccine strategy in emerging markets.